Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000078265 | SCV000110105 | uncertain significance | not provided | 2013-08-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001854373 | SCV002182358 | uncertain significance | Fabry disease | 2021-10-10 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 92540). This sequence change replaces glutamine with proline at codon 416 of the GLA protein (p.Gln416Pro). The glutamine residue is weakly conserved and there is a moderate physicochemical difference between glutamine and proline. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with GLA-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). Experimental studies have shown that this missense change affects GLA function (PMID: 23935525). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV000078265 | SCV003816833 | uncertain significance | not provided | 2022-06-09 | criteria provided, single submitter | clinical testing |